|
|
|
 |
| |
| Carcinogenesis,
Teratogenesis & Mutagenesis
The forth Editorial Board
|
|
Hu
Yiping |
|
| |
|
Male,
borned in Jun.1954, Ph.D., professor, the adviser
of Ph.D. candidate. He is the directors of the
Cell Biology Department and the Transgenic Animal
Laboratory of the Second Military Medical University
and the associate director of the Opening laboratory
of Molecular Genetics of PLA. Also he is the
editor in chief of Medical Cell Biology,which
is a National textbook for medical students.
During 1984 to 1992, he studied under professor
Zudong Liu in the Genetic Research Institute
of Fudan University as candidates of master
degree and the doctor degree. During 1994 to
1997, he worked as a postdoctor in professor
Paul Soloway's laboratory of Roswell Park cancer
Institute in America. Then cooperative study
was proceeded in the same laboratory during
2000 to 2001. In 1993,he was elected into the
Shanghai Rising-star program and earns the special
allowance of Shanghai Government. In 1997, he
was selected as one of the Shanghai Eminent
Returned Scholars and won Shanghai Education
Award, being sponsored by a specific foundation.
In 1998, he was named as the "Excellent
Teacher" by the general Logistics Department
of PLA. In 2000, he was judged the “Excellent
Teacher” by the National Ministry of Education
and was funded. Currently, he is filling the
following academic posts: a member of the academic
committee of the Stem Cell Key Laboratory in
Chinese Academy of Sciences; the committeeman
of the academic committee of the Shanghai Research
Center for Biomodel Organism of the National
Ministry of Science and Technology; the voice-secretary
general of the Chinese Environmental Mutagen
Society; a member of the executive council of
the Chinese Society for Cell Biology; the director
of the Chinese Genetic Society; the standing
committeeman of the Chinese Society of Cellular
Biology and Biology Group of the Medical Education
of the Chinese Medical Association; the vice
president of the executive council of the Shanghai
Society for Cell Biology; the director of the
Shanghai Society for Laboratory Animal and et,
al. He once assumed the office of the under-secretary
general of the Shanghai Genetic Society and
the director of the committee of the Society
for Human and Medical Genetics. He is charged
with a series of scientific research projects
from the nation(863 project, and key projects),
army and Shanghai Government. He has achieved
several scientific payoffs such as the "HBV
transgenic mouse model"(it was listed as
one of the "Ten Important News in Chinese
medical fields" in 1997). He has published
more than 120 research papers on the journals.
He has edited 2 textbooks and 1 monographes
in chief and joined the edition of 9 monographes.
He is also the members of an editorial board
of The Great Encyclopedia Dictionary of
the Chinese Language, e.g.CiHai Dictionary,
and Encyclopedia of China(genetics volume).
|
|
| |
|
|
|
| |
 |
| |
 |
| Cheng
Shujun is currently as a professor of Cancer
Institute (Hospital), Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, China,
and Chief Scientist of both China State Key Basic
Research Project “Fundamental investigation of human
carcinogenesis and cancer therapy and prevention”
and Beijing key Cancer Research Project “Tumor biomarker
profiling and human cancer diagnosis and therapy”.
He worked as a visiting scientist in Laboratoire de
Medicine Experimental, Institute de la Recherches
Scientifiques sur le Cancer, France (1978-1981), and
in Department of Pathology, Medical College of Ohio,
USA (1986-1987). He has established a series of short-term
tests for the detection of environmental carcinogens
and anti-carcinogens in China. He was elected as a
Member, Chinese Academy of Engineering in 1999. Dr.
Cheng is the President of Chinese Environmental Mutagen
Society, and Vice President of China Anticancer Association.
He found that the tea catechins showed a significant
inhibitory effect against human genital condylomas
and inflammatory hyperplasia. Based on the invention,
he and his collaborators had received international
patents “Composition for treating condyloma acuminate”
in 1998. This invention had been approved to go for
clinical phase III trial by US FDA. As invited speakers,
Dr. Cheng has visited many institutes at foreign countries
and attended at international conferences. |
|
| |
|
